Stemline Therapeutics (STML) Downgraded by BidaskClub
Stemline Therapeutics (NASDAQ:STML) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.
Several other research firms have also recently weighed in on STML. HC Wainwright reissued a “buy” rating and set a $38.00 price target on shares of Stemline Therapeutics in a report on Friday, November 10th. Cowen reissued a “buy” rating on shares of Stemline Therapeutics in a report on Tuesday, October 31st. Finally, ValuEngine cut Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $33.40.
Stemline Therapeutics (NASDAQ:STML) traded up $0.45 during mid-day trading on Thursday, reaching $14.97. The company had a trading volume of 214,681 shares, compared to its average volume of 274,766. Stemline Therapeutics has a fifty-two week low of $5.50 and a fifty-two week high of $15.95.
WARNING: “Stemline Therapeutics (STML) Downgraded by BidaskClub” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/07/stemline-therapeutics-stml-downgraded-by-bidaskclub.html.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.